medigraphic.com
Instituto Nacional de Salud Pública

2025, Number 3

<< Back Next >>

salud publica mex 2025; 67 (3)

Ovarian Consensus members. Clinical practice guideline for the diagnosis and management of epithelial ovarian cancer

Morales-Vásquez F, Cano-Blanco C, Pérez-Quintanilla M, Alvarado-Cabrero I, Ruvalcaba-Limón E, Salas-González E, Arteaga-Gómez AC, Gómez-García EM, Salcedo-Hernández RA, Cantón-Romero JC, Cortés-Esteban P, Alanís-López P, Enriquez-Aceves MI, Palma-Valle IM, Domínguez-Ocadio G, Pacheco-Bravo I, Gutiérrez-Torres S, Cantú-de León DF

Language: Spanish
References: 70
Page: 287-298
PDF size: 303.93 Kb.


ABSTRACT

Objective. To develop recommendations on the diagnosis, treatment and surveillance of epithelial ovarian cancer (EOC) by consensus. Materials and methods. The consensus was done through a modified Delphi panel. A committee defined 12 main topics and assigned a working group of specialists per topic where the specialists voted on whether the recommendation was appropriate for inclusion in the report with a concordance of 50% +1. Results. A consensus was reached on 56 recommendations based on the scientific evidence identified and evaluated by the group of experts who, through a formal consensus, agreed on the final wording of the clinical recommendations. Conclusion. The present guidelines provide clinical recommendations for the diagnosis and management of the different stages of EOC, which contributes to the continuous improvement of the quality of care for cancer patients in Mexico.


REFERENCES

  1. Morales-Vásquez F, Cano-Blanco C, Cantú-de León DF. Quinto consensode ovario. México: figshare, 2025 [citado agosto 2024]. Disponible en:https://doi.org/10.6084/m9.figshare.c.7643942.v1

  2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, etal. Global cancer statistics 2020: GLOBOCAN estimates of incidence andmortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin.2021;71(3):209-49. https://doi.org/10.3322/caac.21660

  3. Gallardo-Rincón D, Espinosa-Romero R, Muñoz WR, Mendoza-MartínezR, del Villar-Álvarez S, Oñate-Ocaña L, et al. Epidemiological overview,advances in diagnosis, prevention, treatment and management of epithelialovarian cancer in Mexico. Salud Publica Mex. 2016;58(2):302-8. https://doi.org/10.21149/spm.v58i2.7801

  4. Martínez-Sahuquillo Amuedo ME, Echeverría-Ruiz de Vargas MC.Métodos de consenso. Uso adecuado de la evidencia en la toma dedecisiones. Rehabilitacion. 2001;35(6):388-92. https://doi.org/10.1016/S0048-7120(01)73220-3

  5. Yarmolinsky J, Relton CL, Lophatananon A, Muir K, Menon U, Gentry-Maharaj A, et al. Appraising the role of previously reported risk factorsin epithelial ovarian cancer risk: a Mendelian randomization analysis.PLoS Med. 2019;16(8):e1002893. https://doi.org/10.1371/journal.pmed.1002893

  6. Sánchez-Borrego R, Sánchez-Prieto M. What are the mechanisms of actionof the different contraceptive methods to reduce the risk of ovariancancer? Eur J Contracept Reprod Health Care. 2021;26(1):79-84. https://doi.org/10.1080/13625187.2020.1849617

  7. National Institute for Health and Care Excellence. Surveillance report(exceptional review) 2017 – Ovarian cancer: recognition and initialmanagement (2011) NICE guideline CG122. Londres: NICE, 2017 [citadoagosto 2024]. Disponible en: www.nice.org.uk/guidance/cg122

  8. Rosenthal AN, Menon U, Jacobs IJ. Screening for ovarian cancer. ClinObstet Gynecol. 2006;49(3):433-47. https://doi.org/10.1097/00003081-200609000-00004

  9. Teh BH, Yong SL, Sim WW, Lau KB, Suharjono HN. Evaluation in thepredictive value of serum human epididymal protein 4 (HE4), cancerantigen 125 (CA125) and a combination of both in detecting ovarianmalignancy. Horm Mol Biol Clin Investig. 2018;35(1):20180029. https://doi.org/10.1515/hmbci-2018-0029

  10. Salim E, Zubairi AM, Danish SH, Ali U. Diagnostic accuracy of risk ofovarian malignancy algorithm (ROMA) in post-menopausal patients withovarian mass. J Coll Physicians Surg Pak. 2018;28(6):440-4. https://doi.org/10.29271/jcpsp.2018.06.440

  11. Köbel M, Bak J, Bertelsen BI, Carpen O, Grove A, Hansen ES, et al.Ovarian carcinoma histotype determination is highly reproducible andis improved through the use of immunohistochemistry. Histopathology.2014;64(7):1004-13. https://doi.org/10.1111/his.12349

  12. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview.Int J Gynecol Pathol. 2008;27(2):161-74. https://doi.org/10.1097/PGP.0b013e31815ea812

  13. Evans M. Immunohistochemistry and molecular testing in gynecologicalpathology. Mini-symposium: gynecological pathology. Diagn Histopath.2022;28(8):353-63. https://doi.org/10.1016/j.mpdhp.2022.05.006

  14. Cheng A, Li L, Wu M, Lang J. Pathological findings following riskreducingsalpingo-oophorectomy in BRCA mutation carriers: a systematicreview and meta-analysis. Eur J Surg Oncol. 2020;46(1):139-47. https://doi.org/10.1016/j.ejso.2019.09.002

  15. AlHilli MM, Batur P, Hurley K, Al-Hilli Z, Coombs D, Schwarz G, et al.Comprehensive care of women with genetic predisposition to breastand ovarian cancer. Mayo Clin Proc. 2023;98(4):597-609. https://doi.org/10.1016/j.mayocp.2023.01.001

  16. Finch AP, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, et al. Impactof oophorectomy on cancer incidence and mortality in women with aBRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32(15):1547-53. https://doi.org/10.1200/JCO.2013.53.2820

  17. Capasso I, Santoro A, Lucci-Cordisco E, Perrone E, Tronconi F,Catena U, et al. Lynch syndrome and gynecologic tumors: incidence,prophylaxis, and management of patients with cancer. Cancers (Basel).2023;15(5):1400. https://doi.org/10.3390/cancers15051400

  18. Ludwig KK, Neuner J, Butler A, Geurts JL, Kong AL. Risk reductionand survival benefit of prophylactic surgery in BRCA mutation carriers, asystematic review. Am J Surg. 2016;212(4):660-9. https://doi.org/10.1016/j.amjsurg.2016.06.010

  19. Powell CB, Chen LM, McLennan J, Crawford B, Zaloudek C, RabbanJT, et al. Risk-reducing salpingo-oophorectomy (RRSO) in BRCAmutation carriers: experience with a consecutive series of 111 patientsusing a standardized surgical-pathological protocol. Int J Gynecol Cancer.

  20. 2011;21(5):846-51. https://doi.org/10.1097/igc.0b013e31821bc7e320. La Verde M, Riemma G, Tropea A, Biondi A, Cianci S. Ultra-minimallyinvasive surgery in gynecological patients: a review of the literature.Updates Surg. 2022;74(3):843-55. https://doi.org/10.1007/s13304-022-01248-y

  21. Cianci S, Perrone E, Rossitto C, Fanfani F, Tropea A, Biondi A, et al.Percutaneous-assisted vs mini-laparoscopic hysterectomy: comparison ofultra-minimally invasive approaches. Updates Surg. 2021;73(6):2347-54.https://doi.org/10.1007/s13304-020-00893-5

  22. Trillsch F, Mahner S, Vettorazzi E, Woelber L, Reuss A, BaumannK, et al. Surgical staging and prognosis in serous borderline ovariantumours (BOT): a subanalysis of the AGO ROBOT study. Br J Cancer.2015;112(4):660-6. https://doi.org/10.1038/bjc.2014.648

  23. Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY, et al. Randomizedphase III trial of three versus six cycles of adjuvant carboplatinand paclitaxel in early-stage epithelial ovarian carcinoma: a GynecologicOncology Group study. Gynecol Oncol. 2006;102(3):432-9. https://doi.org/10.1016/j.ygyno.2006.06.013

  24. Knisely A, Gamble CR, St Clair CM, Hou JY, Khoury-Collado F,Gockley AA, et al. The role of minimally invasive surgery in the care ofwomen with ovarian cancer: a systematic review and meta-analysis. JMinim Invasive Gynecol. 2021;28(3):537-43. https://doi.org/10.1016/j.jmig.2020.11.007

  25. Poncelet C, Fauvet R, Boccara J, Daraï E. Recurrence after cystectomyfor borderline ovarian tumors: results of a French multicenterstudy. Ann Surg Oncol. 2006;13(4):565-71. https://doi.org/10.1245/ASO.2006.12.024

  26. Fagotti A, Ferrandina G, Fanfani F, Ercoli A, Lorusso D, Rossi M, et al. Alaparoscopy-based score to predict surgical outcome in patients with advancedovarian carcinoma: a pilot study. Ann Surg Oncol. 2006;13(8):1156-61. https://doi.org/10.1245/ASO.2006.08.021

  27. Purwar R, Ranjan R, Soni K, Pandey M, Upadhyay SK, Pai E, et al.Lymphadenectomy in ovarian cancers: a meta-analysis of hazard ratiosfrom randomized clinical trials. World J Surg Oncol. 2022;20(1):367.https://doi.org/10.1186/s12957-022-02835-4

  28. Kim SI, Kim JH, Lee S, Cho H, van Driel WJ, Sonke GS, et al. Hyperthermicintraperitoneal chemotherapy for epithelial ovarian cancer: ameta-analysis. Gynecol Oncol. 2022;167(3):547-56. https://doi.org/10.1016/j.ygyno.2022.10.010

  29. Fotopoulou C, Jones BP, Savvatis K, Campbell J, Kyrgiou M, FarthingA, et al. Maximal effort cytoreductive surgery for disseminated ovariancancer in a UK setting: challenges and possibilities. Arch Gynecol Obstet.2016;294(3):607-14. https://doi.org/10.1007/s00404-016-4080-3

  30. Chalif J, Yao M, Gruner M, Kuznicki M, Vargas R, Rose PG, et al. Incidenceand prognostic significance of inguinal lymph node metastasis inwomen with newly diagnosed epithelial ovarian cancer. Gynecol Oncol.2022;165(1):90-6. https://doi.org/10.1016/j.ygyno.2022.01.026

  31. Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, BradyMF, et al. Final overall survival of a randomized trial of bevacizumab forprimary treatment of ovarian cancer. J Clin Oncol. 2019;37(26):2317-28.https://doi.org/10.1200/JCO.19.01009

  32. Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, FriedlanderM, et al. Maintenance olaparib in patients with newly diagnosed advancedovarian cancer. N Engl J Med. 2018;379(26):2495-505. https://doi.org/10.1056/NEJMoa1810858

  33. González-Martín A, Pothuri B, Vergote I, DePont-Christensen R,Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosedadvanced ovarian cancer. N Engl J Med. 2019;381(25):2391-402. https://doi.org/10.1056/NEJMoa1910962

  34. du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, BookmanM, et al. 2004 consensus statements on the management of ovariancancer: final document of the 3rd International Gynecologic Cancer IntergroupOvarian Cancer Consensus Conference (GCIG OCCC 2004). AnnOncol. 2005;16(suppl 8):viii7-12. https://doi.org/10.1093/annonc/mdi961

  35. Stuart GCE, Kitchener H, Bacon M, duBois A, Friedlander M,Ledermann J, et al. 2010 Gynecologic Cancer InterGroup (GCIG)consensus statement on clinical trials in ovarian cancer: report from theFourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer.2011;21(4):750-5. https://doi.org/10.1097/IGC.0b013e31821b2568

  36. Berek JS, Kehoe ST, Kumar L, Friedlander M. Cancer of the ovary,fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2018;143(suppl2):59-78. https://doi.org/10.1002/ijgo.12614

  37. Kleppe M, Wang T, Van Gorp T, Slangen BF, Kruse AJ, Kruitwagen RF.Lymph node metastasis in stages I and II ovarian cancer: a review. GynecolOncol. 2011;123(3):610-4. https://doi.org/10.1016/j.ygyno.2011.09.013

  38. Salgado-Ceballos I, Ríos J, Pérez-Montiel D, Gallardo L, Barquet-MuñozS, Salcedo-Hernández R, et al. Is lymphadenectomy necessary in mucinousovarian cancer? A single institution experience. Int J Surg. 2017;41:1-5.https://doi.org/10.1016/j.ijsu.2017.03.023

  39. Zhou J, Zhang WW, Zhang QH, He ZY, Sun JY, Chen QH, et al. Theeffect of lymphadenectomy in advanced ovarian cancer according toresidual tumor status: a population-based study. Int J Surg. 2018;52:11-5.https://doi.org/10.1016/j.ijsu.2018.02.006

  40. Naumann RW, Hughes BN, Brown J, Drury LK, Herzog TJ. The impactof opportunistic salpingectomy on ovarian cancer mortality and healthcarecosts: a call for universal insurance coverage. Am J Obstet Gynecol.2021;225(4):397.e1-6. https://doi.org/10.1016/j.ajog.2021.03.032

  41. Committee on Practice Bulletins–Gynecology, Committee onGenetics, Society of Gynecologic Oncology. Practice bulletin No 182:hereditary breast and ovarian cancer syndrome. Obstet Gynecol.2017;130(3):e110-26. https://doi.org/10.1097/AOG.0000000000002296

  42. AlHilli MM, Al-Hilli Z. Perioperative management of women undergoingrisk-reducing surgery for hereditary breast and ovarian cancer. JMinim Invasive Gynecol. 2019;26(2):253-65. https://doi.org/10.1016/j.jmig.2018.09.767

  43. 43 Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosisand staging of patients with peritoneal carcinomatosis. Cancer Treat Res.1996;82:359-74. https://doi.org/10.1007/978-1-4613-1247-5_23

  44. Hiu S, Bryant A, Gajjar K, Kunonga PT, Naik R. Ultra-radical (extensive)surgery versus standard surgery for the primary cytoreductionof advanced epithelial ovarian cancer. Cochrane Database Syst Rev.2022;8(8):CD007697. https://doi.org/10.1002/14651858.CD007697.pub3

  45. Shi T, Zhu J, Feng Y, Tu D, Zhang Y, Zhang P, et al. Secondary cytoreductionfollowed by chemotherapy versus chemotherapy alone in platinumsensitiverelapsed ovarian cancer (SOC-1): a multicentre, open-label,randomised, phase 3 trial. Lancet Oncol. 2021;22(4):439-49. https://doi.org/10.1016/S1470-2045(21)00006-1

  46. Tew WP, Lacchetti C, Kohn EC. Poly(ADP-Ribose) polymeraseinhibitors in the management of ovarian cancer: ASCO guideline rapidrecommendation update. J Clin Oncol. 2022;40(33):3878-81. https://doi.org/10.1200/JCO.22.01934

  47. Pignata S, Lorusso D, Joly F, Gallo C, Colombo N, Sessa C, et al.Carboplatin-based doublet plus bevacizumab beyond progression versuscarboplatin-based doublet alone in patients with platinum-sensitive ovariancancer: a randomised, phase 3 trial. Lancet Oncol. 2021;22(2):267-76.https://doi.org/10.1016/S1470-2045(20)30637-9

  48. Singh P, Singh D, Anant M, Agrawal M, Sinha R. Clinical characteristicsand treatment outcomes of patients with ovarian germ cell tumortreated at a tertiary care center in Patna, India. Indian J Gynecol Oncol.2020;18(77):1-8. https://doi.org/10.1007/s40944-020-00401-y

  49. Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, et al. Analysis ofoutcomes and prognostic factors after fertility-sparing surgery in malignantovarian germ cell tumors. Gynecol Oncol. 2017;145(3):513-8. https://doi.org/10.1016/j.ygyno.2017.03.023

  50. Cardenas-Goicoechea J, Wang Y, McGorray S, Saleem MD, Carbajal-Mamani SL, Pomputius AF, et al. Minimally invasive interval cytoreductivesurgery in ovarian cancer: systematic review and meta-analysis. J RobotSurg. 2018;13(1):23-33. https://doi.org/10.1007/s11701-018-0838-x

  51. Ray-Coquard I, Morice P, Lorusso D, Prat J, Oaknin A, Pautier P, etal. Non-epithelial ovarian cancer: ESMO clinical practice guidelines fordiagnosis, treatment and follow-up. Ann Oncol. 2018;29(suppl 4):iv1-18.https://doi.org/10.1093/annonc/mdy001

  52. Gershenson DM. Management of ovarian germ cell tumors. J ClinOncol. 2007;25(20):2938-43. https://doi.org/10.1200/JCO.2007.10.8738

  53. Lim D, Oliva E. Ovarian sex cord-stromal tumours: an update inrecent molecular advances. Pathology. 2018;50(2):178-89. https://doi.org/10.1016/j.pathol.2017.10.008

  54. Zhang M, Cheung MK, Shin JY, Kapp DS, Husain A, Teng NN, et al. Prognosticfactors responsible for survival in sex cord stromal tumors of theovary--an analysis of 376 women. Gynecol Oncol. 2007;104(2):396-400.https://doi.org/10.1016/j.ygyno.2006.08.032

  55. Torres-Morcillo C, Delgado-Espárrago L, Couso-González A. Tumorde células de la granulosa del ovario de tipo adulto: revisión de 7 casos.Clin Invest Ginecol Obst. 2019;46(1):28-34. https://doi.org/10.1016/j.gine.2018.11.001

  56. Crawford GB, Dzierżanowski T, Hauser K, Larkin P, Luque-Blanco AI,Murphy I, et al. Care of the adult cancer patient at the end of life: ESMOclinical practice guidelines. ESMO Open. 2021;6(4):100225. https://doi.org/10.1016/j.esmoop.2021.100225

  57. Anthony T, Baron T, Mercadante S, Green S, Chi D, CunninghamJ, et al. Report of the clinical protocol committee: development ofrandomized trials for malignant bowel obstruction. J Pain SymptomManage. 2007;34(suppl 1):S49-59. https://doi.org/10.1016/j.jpainsymman.2007.04.011

  58. Ferrell BR, Temel JS, Temin S, Alesi ER, Balboni TA, Basch EM, et al.Integration of palliative care into standard oncology care: ASCO clinicalpractice guideline update summary. J Oncol Pract. 2017;13(2):119-21.https://doi.org/10.1200/JCO.2016.70.1474

  59. Secretaría de Salud. Decreto por el que se reforma el artículo 184de la Ley General de Salud y se adiciona el artículo 166 Bis que contienela Ley en Materia de Cuidados Paliativos. México: Diario Oficial de laFederación, 2009 [citado agosto 2024]. Disponible en: https://www.calidad.salud.gob.mx/site/calidad/docs/dmp-paliar_00C.pdf

  60. Atri M, Alabousi A, Reinhold C, Akin EA, Benson CB, Bhosale PR, et al.ACR appropriateness criteria® clinically suspected adnexal mass, no acutesymptoms. J Am Coll Radiol. 2019;16(5S):S77-93. https://doi.org/10.1016/j.jacr.2019.02.011

  61. Timmerman D, Planchamp F, Bourne T, Landolfo C, du Bois A, Chiva L,et al. ESGO/ISUOG/IOTA/ESGE Consensus statement on pre-operativediagnosis of ovarian tumors. Ultrasound Obstet Gynecol. 2021;58(1):148-68. https://doi.org/10.1002/uog.23635

  62. Booth SJ, Turnbull LW, Poole DR, Richmond I. The accurate stagingof ovarian cancer using 3T magnetic resonance imaging--a realisticoption. BJOG. 2008;115(7):894-901. https://doi.org/10.1111/j.1471-0528.2008.01716.x

  63. Cui L, Xu H, Zhang Y. Diagnostic accuracies of the ultrasound andmagnetic resonance imaging ADNEX scoring systems for ovarian adnexalmass: systematic review and meta-analysis. Acad Radiol. 2022;29(6):897-908. https://doi.org/10.1016/j.acra.2021.05.029

  64. Tsili AC, Naka C, Argyropoulou MI. Multidetector computedtomography in diagnosing peritoneal metastases in ovariancarcinoma. Acta Radiol. 2021;62(12):1696-706. https://doi.org/10.1177/0284185120980006

  65. Rizzo S, Del Grande M, Manganaro L, Papadia A, Del Grande F. Imagingbefore cytoreductive surgery in advanced ovarian cancer patients. IntJ Gynecol Cancer. 2020;30(1):133-8. https://doi.org/10.1136/ijgc-2019-000819

  66. Nougaret S, Vargas HA, Sala E. BJR female genitourinary oncology specialfeature: introductory editorial. Br J Radiol. 2021;94(1125):20219003.https://doi.org/10.1259/bjr.20219003

  67. Buonomo F, Bussolaro S, de Almeida-Fiorillo C, Oliveira-de Souza D,Giudici F, Romano F, et al. Ultrasound-guided tru-cut biopsy in gynecologicaland non-gynecological pelvic masses: a single-center experience. J ClinMed. 2022;11(9):2534. https://doi.org/10.3390/jcm11092534

  68. Shen J, Tao Y, He L, Guan H, Zhen H, Liu Z, et al. Clinical applicationof radiotherapy in patients with oligometastatic ovarian cancer: a sharptool to prolong the interval of systemic treatment. Discov Oncol.2022;13(1):82. https://doi.org/10.1007/s12672-022-00540-y

  69. Butala AA, Patel RR, Manjunath S, Latif NA, Haggerty AF, Jones JA, et al. Palliativeradiation therapy for metastatic, persistent, or recurrent epithelial ovariancancer: efficacy in the era of modern technology and targeted agents. AdvRadiat Oncol. 2020;6(1):100624. https://doi.org/10.1016/j.adro.2020.11.009

  70. Lee BM, Lee SJ, Kim N, Byun HK, Kim YB. Radiotherapy in recurrent ovariancancer: updated results of involved-field radiation therapy. Int J GynecolCancer. 2023;33(7):1106-11. https://doi.org/10.1136/ijgc-2022-004200




2020     |     www.medigraphic.com